RNA-based Therapeutics and Vaccine Market

RNA-based Therapeutics and Vaccine Market Outlook (2024 to 2034)

Valuation of the global RNA-based therapeutics and vaccine market is evaluated to increase from US$ 180.5 million in 2024 to US$ 1.24 billion by the end of 2034. Revenue in the market has been forecasted to rise at a remarkable CAGR of 21.3% from 2024 to 2034.

As the medical industry progresses, the market for RNA-based therapeutics and vaccines is likely to attract more attention, with an increasing number of doctors and scientists investing their efforts to harness its benefits.

RNA-based therapeutics have sparked significant discussion due to their immense potential in treating chronic diseases. Moreover, RNA immunizations offer advantages over gene delivery in terms of effectiveness, manufacturing, and distribution. These qualities are encouraging more doctors to adopt this therapy, contributing to RNA-based therapeutics and vaccine market growth.

Since mRNA treatments and immunizations have demonstrated promise in human clinical trials, demand for them has surged. In addition, the success of COVID-19 vaccines by Moderna and Pfizer-BioNTech has led to a marked increase in the exploration of protein expression vaccine therapies in cancer clinical research.

Key Market Growth Drivers

• RNA aptamers are used to inhibit a specific protein from binding to its cell membrane receptor or to obstruct a protein's activity by attaching to its target.
• They offer an excellent alternative to traditional drugs, effectively treating diseases and gaining popularity among individuals seeking novel treatments beyond conventional medicines.
• A diverse range of diseases, including genetic disorders, viral infections, cancer, neurodivergent conditions, and cardiovascular diseases, are being treated with RNA-based therapeutics.

Report Attribute	Detail
RNA-based therapeutics and Vaccine Market Size (2024E)	US$ 180.5 Million
Forecasted Market Value (2034F)	US$ 1.24 Billion
Global Market Growth Rate (2024 to 2034)	21.3% CAGR
Canada Market Growth Rate (2024 to 2034)	19.5% CAGR
China Market Value (2034F)	US$ 56 Million
North America Market Share (2024E)	42.6%
East Asia Market Share (2034F)	11.5%
Key Companies Profiled	Alnylam Pharmaceuticals Inc.; Arbutus Biopharma Corp.; Arrowhead Pharmaceuticals Inc.; BioNTech AG; Dicerna Pharmaceuticals Inc; Regulus Therapeutics Inc.; Marina Biotech Inc.; Moderna Therapeutics Inc.; Santaris Pharma A/S.

Which Key Developments are Benefitting Companies in This Market?

“Growing Emphasis on Developing Advanced Treatments for Rare and Chronic Illnesses”

RNA-based biopharmaceuticals, often called RNA-based therapies and vaccines, are viewed as advanced treatments and preventatives for various rare and chronic illnesses, including cancer, tuberculosis, diabetes, and cardiovascular disorders.

• On March 5, 2024, the FDA approved the first cancer TIL therapy for advanced melanoma, which is meant to ease the process for oncologists.
• June 2024 saw the introduction of RNA Direct Injection, a novel approach to cancer treatment, immune system impairment, and gene therapy, transforming the oncology sector.

“Increasing Adoption of RNA Interference, Antisense, and Smart Technologies”

RNA therapies and vaccines are unique in that they offer superior stability when compared to other treatments. When it comes to treating obstinate problems, they are becoming more and more popular, even if the bulk of them are still in trials as previously indicated.

Technologies that are being quickly embraced are RNA interference, antisense, and smart technologies. These are major RNA-based therapeutics and vaccine market trends that players are leveraging. Researchers have been focusing on RNAi and antisense technologies because they aid in providing the base sequence needed to produce RNA medicines. It should not be assumed that both technologies operate in the same way, though. Whereas RNAi technology entails the destruction of certain mRNA molecules, antisense technology creates an RNA strand from a known gene sequence.

“Focused Research Collaborations on Rare Genetic Diseases”

Several market collaborations are strengthening the market by allowing new players to enter, establish their positions, invest their knowledge, and stimulate growth.

• In January 2022, Pfizer Inc. and Beam Therapeutics Inc. entered a four-year exclusive research collaboration focused on in vivo base editing programs targeting three rare genetic diseases affecting the liver, muscle, and central nervous system.

What are the Factors Limiting Market Opportunities for Companies?

“Recalls or Discontinuation of RNA-Based Therapeutics Products Affecting Trust”

Recalls or discontinuations can occur due to various reasons, such as unexpected side effects, safety concerns, efficacy issues, or noncompliance with regulations. These events can undermine trust in RNA therapeutic products among consumers and healthcare professionals, leading to reduced adoption and demand.

Withdrawals or recalls can affect the reputation of involved firms and public perception of RNA therapies as promising treatment options. Investors may also become cautious and reduce their support for research and development in the sector. Regulatory authorities may tighten rules, resulting in more stringent approval processes. All of these factors are impeding the expansion of the RNA-based therapeutics and vaccine market size.

“High Immunogenicity of Exogenous RNA Hindering Therapeutic Application”

Exogenous RNA is rapidly degraded by ubiquitous RNases in tissues and the environment when it is highly immunogenic. There are several obstacles in the way of RNA therapies' advancement, which has made creative methods for their development and production necessary.

One of the main challenges is the intrinsic vulnerability of foreign RNA to fast destruction by omnipresent RNases found in tissues and the environment. Effectively delivering negatively charged RNA molecules through hydrophobic cytoplasmic membranes of target cells is another crucial challenge. Additionally, a significant barrier to overcome is the cell toxicity and hindrance to RNA translation into therapeutic proteins due to the high immunogenicity of exogenous RNA.

“Substantial Research Costs Associated with RNA-Based Therapies”

The market for RNA-based vaccines and treatments is susceptible to high research costs and a higher failure rate in clinical trials. Additionally, challenges in medication distribution cannot be overlooked. The rising costs of research may compel developing economies to reassess their participation in this field.

Country-wise Analysis

The South Korea market is calculated to expand at a remarkable CAGR of 22.3% from 2024 to 2034. The country is set to occupy an RNA-based therapeutics and vaccine market share of 24.7% in East Asia by the end of 2034.

Why Does the United States Hold a Leading Position in the Global Market?

“Focus on Healthcare Advancements and Rising Government Investments in RNA-Based Technology”

Attribute	United States
Market Value (2024E)	US$ 69 Million
Growth Rate (2024 to 2034)	19.8% CAGR
Projected Value (2034F)	US$ 418 Million

The United States holds a leading position in the global market. This is attributed to technological advancements and the increasing incidence of chronic diseases. Moreover, the government is investing significantly in research to advance RNA-based technology.

• To learn more about the functioning of RNA particles, Rochester and Albany established a new Center of Excellence in RNA research on May 10, 2024.
• To better understand the untapped potential of ribonucleic acid (RNA) for potentially far-reaching biotechnology applications, from disease prevention in crops to cancer-fighting therapies, the U.S. National Science Foundation awarded over US$ 12.7 million in February 2024 to nine research teams. Through the Molecular Foundations for Biotechnology (MFB) initiative, which is a collaborative endeavor between NSF and the National Human Genome Research Institute (NHGRI) of the National Institutes of Health, the nine teams will each receive US$ 1 million to US$ 1.65 million from NSF.

What Makes China a Lucrative Market for RNA-based Therapeutics Providers?

“Focus on Research into Single-stranded Nucleic Acid”

Attribute	China
Market Value (2024E)	US$ 7 Million
Growth Rate (2024 to 2034)	23.7% CAGR
Projected Value (2034F)	US$ 56 Million

Single-stranded nucleic acid molecules known as RNA aptamers have a high degree of selectivity and affinity when binding to particular targets. Numerous therapeutic uses, such as those for infectious disorders, heart conditions, and cancer, have been studied. One significant area of market opportunity is the advancement in the creation of medicines based on RNA aptamer technology. This is due to the several potential benefits that RNA aptamers offer over conventional medication therapy.

• The modular gene-editing system known as CyDENT was disclosed by researchers at the Chinese Academy of Sciences Institute of Genetics and Developmental Biology in the journal Nature Biotechnology on August 28.
• On March 22, 2023, Chinese authorities authorized the first mRNA vaccine produced domestically by pharmaceutical company CSPC.

Category-wise Evaluation

Based on indication, genetic diseases are projected to account for 59% share of overall revenue by 2034.

Why Do RNA-Based Therapeutics Hold a Larger Market Share Compared to Vaccines?

“Commitment of Researchers to Innovation in RNA-based Therapeutics Due to Their Efficacy”

Attribute	RNA-based Therapeutics
Segment Value (2024E)	US$ 180.5 Million
Growth Rate (2024 to 2034)	20% CAGR
Projected Value (2034F)	US$ 1.12 Billion

Among RNA-based therapeutics and vaccines, the therapeutics segment is expected to capture a larger market share in 2024 due to its significant influence on addressing several diseases. Doctors are dedicating their time to developing and advancing innovations in this field.

Why are Doctors and Scientists Focusing on RNA-Based Techniques in Genetic Disease Research?

“RNA-based Techniques Facilitating Speedy Exploration of Treatments for Genetic Diseases”

Attribute	Genetic Diseases
Segment Value (2024E)	US$ 136.7 Million
Growth Rate (2024 to 2034)	18.2% CAGR
Projected Value (2034F)	US$ 730.6 Million

RNA-based therapeutics effectively assess the body's condition and provide precise results that can be utilized for medical examinations. Increasingly, doctors and scientists are choosing this method to swiftly explore treatments for genetic diseases.

Market Rivalry

Key players in the RNA-based therapeutics and vaccine market are pursuing every avenue of growth, including joint ventures, partnerships, the introduction of new medications and vaccines, acquisitions, mergers, and other means to stay ahead of the competition. They are adapting to evolving market trends such as focusing on peptide-based infection therapeutics, arthritis therapeutics, and osteoporosis therapeutics.

• Acuitas Medicines and Pfizer signed a 'development and option agreement' on January 10, 2022, allowing Pfizer to license the latter's LNP technology for nearly ten targets for the development of medicines or vaccines. This would be provided without restriction.

Fact.MR provides detailed information about the price points of key RNA-based therapeutics and vaccine providers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Key Segments of RNA-based Therapeutics and Vaccine Market Research

• By Product Type :

  • RNA-based Therapeutics
  • RNA-based Vaccines (mRNA)

• By Indication :

  • Oncology
  • Immunology
  • Ophthalmology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Genetic Diseases
  • Others

• By Region :

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa